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ARTICLE
Sustained microglial depletion with CSF1R inhibitor
impairs parenchymal plaque development in an
Alzheimer’s disease model
Elizabeth Spangenberg1, Paul L. Severson2, Lindsay A. Hohsfield1, Joshua Crapser1, Jiazhong Zhang2,
Elizabeth A. Burton2, Ying Zhang2, Wayne Spevak2, Jack Lin2, Nicole Y. Phan1, Gaston Habets2, Andrey Rymar2,
Garson Tsang2, Jason Walters2, Marika Nespi2, Parmveer Singh2, Stephanie Broome2, Prabha Ibrahim2,
Chao Zhang2, Gideon Bollag2, Brian L. West 2 & Kim N. Green1
Many risk genes for the development of Alzheimer’s disease (AD) are exclusively or highly
expressed in myeloid cells. Microglia are dependent on colony-stimulating factor 1 receptor
(CSF1R) signaling for their survival. We designed and synthesized a highly selective brain-
penetrant CSF1R inhibitor (PLX5622) allowing for extended and specific microglial elimina-
tion, preceding and during pathology development. We find that in the 5xFAD mouse model
of AD, plaques fail to form in the parenchymal space following microglial depletion, except in
areas containing surviving microglia. Instead, Aβ deposits in cortical blood vessels reminis-
cent of cerebral amyloid angiopathy. Altered gene expression in the 5xFAD hippocampus is
also reversed by the absence of microglia. Transcriptional analyses of the residual plaque-
forming microglia show they exhibit a disease-associated microglia profile. Collectively, we
describe the structure, formulation, and efficacy of PLX5622, which allows for sustained
microglial depletion and identify roles of microglia in initiating plaque pathogenesis.
https://doi.org/10.1038/s41467-019-11674-z OPEN
1 Department of Neurobiology and Behavior, University of California Irvine (UCI), Irvine, CA 92697, USA. 2 Plexxikon Inc, Berkeley, CA 94710, USA.
Correspondence and requests for materials should be addressed to K.N.G. (email: kngreen@uci.edu)
NATURE COMMUNICATIONS |         (2019) 10:3758 | https://doi.org/10.1038/s41467-019-11674-z | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
A lzheimer’s disease (AD) is a progressive, age-relatedneurodegenerative disorder thought to be triggered bythe appearance and build-up of amyloid-β (Aβ) plaques in
the cortex1,2. These plaques subsequently spread throughout the
forebrain and lead to a cascade of events, culminating in synaptic
and neuronal loss that underlie the disease-associated memory
impairments. Genome-wide association studies have identified
numerous genes that confer increased risk for developing the
disease; however, the mechanisms underlying plaque formation
remain unclear. Discerning commonalities in the function of
these disease-associated genes may elucidate potential biological
mechanisms involved in the production of plaques3. Several of
the top identified risk-conveying genes are highly enriched in
myeloid cells (CR1, CD33, ABCA7, TREM2, MS4A, EPHA1,
SPI14–6), highlighting the link between myeloid biology and the
risk for developing AD.
Within the CNS, microglia perform homeostatic maintenance,
immune-related, and phagocytic functions. Their reported capa-
city for Aβ phagocytosis and clearance led to the suggestion that
age-related changes in microglial function reduce clearance of
neuronally derived Aβ from the brain7, thus allowing plaque
formation, as modeled in ex-vivo systems8,9. Indeed, we and other
groups report that following the initial period of plaque forma-
tion, microglia surround the plaques and subsequently mount a
harmful and non-resolving inflammatory response. Despite this
response, however, Aβ clearance and plaque modulation/
dynamics is unaffected10–12, yet the removal of the microglia at
advanced stages of pathology protects against synaptic and neu-
ronal loss10.
Here, we set out to explore the contribution(s) of microglia to
plaque formation in the initial stages of the disease, which
requires prolonged depletion of microglia throughout the plaque-
forming period. To that end, we designed, synthesized, and
optimized a potent, specific, orally bioavailable, and brain-
penetrant CSF1R inhibitor, PLX5622, to deplete microglia for
> 6 months in 5xFAD mice. With the elimination of microglia, we
uncovered critical roles of these cells in plaque formation, com-
paction, and growth, mitigating neuritic dystrophy, and mod-
ulating hippocampal neuronal gene expression in response to Aβ
pathology. These results implicate microglia as critical and cau-
sative in the development and progression of multiple facets of
AD pathology.
Results
Microglia contain Aβ aggregates in AD mouse models and
humans. The aggregation of Aβ is an initial step in the formation
of plaques, requiring an acidic pH13 and micromolar con-
centrations of Aβ monomers14. The extracellular space does not
meet these requisite conditions, suggesting that Aβ aggregation
originates elsewhere. In contrast to the extracellular space,
microglial lysosomes provide a suitable environment to facilitate
Aβ aggregation, potentially contributing to the onset of plaque
pathology15. To investigate the potential for microglia-mediated
plaque formation, we examined Aβ aggregates within microglia in
transgenic mouse models of AD. In 15-month-old 3xTg-AD
mice, a time point at which plaques are beginning to form, we
stained tissue for Thio-S (aggregated Aβ), microglia, and lyso-
somes. While plaque-associated microglia show accumulation of
aggregates within their lysosomes (Fig. 1a, b; as well estab-
lished16), we also observed non-plaque-associated microglia,
including ramified microglia, accumulating aggregates within
lysosomal compartments (Fig. 1c, d), and microglia containing
intracellular aggregates the size of small plaques (Fig. 1e, f). The
absence of nearby plaques suggests that existing aggregated Aβ
was not the source of these intracellular deposits. Similarly,
non-plaque-associated microglia in 4- and 7-month old 5xFAD
brains also showed accumulation of Thio-S+ material (Fig. 1g–j).
Additionally, utilizing aged human postmortem brains, including
non-demented, high pathology non-demented, and Alzheimer’s
disease subjects, we again found non-plaque-associated microglia
containing Aβ aggregates (Supplementary Figure 1A–I). Thus,
microglia in plaque forming regions in mouse and human brains
can accumulate aggregated Aβ intracellularly, and we hypothesize
that this could be an initial and crucial step toward plaque
formation.
Development of a CSF1R inhibitor for microglial elimination.
To explore the roles of microglia in the initial development of
plaque pathology, we required a method that allowed for the
extended and specific elimination of microglia throughout the
plaque forming period, using non-invasive/non-stressful
approaches. As we previously demonstrated, microglia are criti-
cally dependent on CSF1R signaling for their survival17, and we
set out to develop specific CSF1R inhibitors that were orally
bioavailable, brain-penetrant, and able to achieve robust brain-
wide microglia elimination for extended periods of time. Using a
structure-guided drug design strategy based on the existing
CSF1R/KIT/FLT3 inhibitor PLX339710,18, combined with in vivo
screening for optimal PK, brain penetrance, and microglial
depletion, we created PLX5622 (Fig. 2a), with crystallography
revealing the interactions between PLX5622 and the CSF1R
(Fig. 2b). The synthesis schematic for the synthesis of PLX5622
and the formation of the optimized PLX5622-fumaric acid salt is
shown (Fig. 2c). Cell free kinase inhibitor profiling revealed that
PLX5622 is highly specific for the CSF1R, showing > 20-fold
selectivity over KIT and FLT3, the two most homologous
receptors (Supplementary Table 2, 3). Two key structural differ-
ences between PLX5622 and PLX3397 contribute to the improved
selectivity based on crystallographic analysis (Fig. 2b; Supple-
mentary Table 4). First, the 2-fluoro substitution on the middle
pyridine ring of PLX5622 is designed to access the CSF1R-unique
space next to Gly-795 (a gate-keeper to the interior allosteric
pocket); both KIT and FLT3 have a bulkier cysteine at the
equivalent position. While the difference between a hydrogen
atom and a fluorine atom may seem small (with slightly longer
bond length and slightly larger radius, a fluorine atom extends the
van der Waals edge by ~ 0.5 Å compared to a hydrogen atom),
the effect is significant. Anchored on both ends by hydrogen
bonds and hydrophobic packing (Fig. 2b), PLX5622 has the
fluorine atom at a fixed position. As van der Waals repulsion
increases in proportion to the 6th power of the distance between
two atoms, a larger gate keeper residue (as seen in KIT and FLT3)
will likely incur an energetic penalty for the steric hindrance. In
support of this mechanism, a close analog of PLX3397 containing
the same 2-fluoro substitution as PLX5622 has the same potency
as PLX3397 in inhibiting CSF1R but is 10-fold more selective over
KIT than PLX3397. Second, the terminal pyridine group of
PLX5622 is optimized to stabilize the allosteric pocket of CSF1R
vacated by the displaced juxtamembrane domain. When
PLX5622 binds to KIT or FLT3, the position and orientation of
the middle pyridine ring causes steric clash with the gate-keeper
cysteine, compromising the optimal fit of the terminal pyridine
moiety.
In vivo PLX5622 demonstrated desirable PK properties in
mice, rats, dogs, and monkeys (Supplementary Table 5), with a
brain penetrance of ~20% (compared to ~5% for PLX339717;
Supplementary Table 6). The improved blood-brain barrier (BBB)
penetrance of PLX5622 over PLX3397 is consistent with the
physicochemical properties of the two compounds (Supplemen-
tary Table 7). PLX5622 has lower molecular weight, higher
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lipophilicity and better cell permeability, all factors known to
influence the ability of a compound to cross the BBB. PLX5622
was formulated in rodent chow, and administration to mice
showed highly effective, causing a 90% reduction with 1200 ppm
chow within 5 days of treatment (Fig. 2d, e). Instructions for the
synthesis and formulation of PLX5622 are provided (Supple-
mentary Methods).
Absence of abnormalities with microglial elimination. Having
designed and optimized PLX5622 for microglia depletion, we
sought to explore the contributions of these cells in the initial
stages of AD pathology. To that end, 5xFAD animals, which
exhibit plaque pathology from 3 months of age, underwent
treatment at 1.5 months of age with PLX5622-formulated chow
(1200 ppm) or control diet continuously for either 10–24 weeks.
Four treatment groups were included: Wild-type, PLX5622,
5xFAD, and 5xFAD+ PLX5622 (n= 12/group; sex-balanced;
Fig. 3a) and initial characterization focused on the 24-week
treated animals. Terminal PK values revealed no differences
between PLX5622-treated groups in either plasma or brain
(Fig. 3b) and no significant differences were seen in circulating
leukocyte subsets (Fig. 3d; Gating strategy in Supplementary
Figure 2) with treatment.
In the brain, 5xFAD mice displayed increased numbers of
microglia/myeloid cells at both 4 and 7 months of age compared
to wild-type mice, with masses of enlarged, plaque-associated
cells seen throughout the brain (Fig. 3c). Oral PLX5622 treatment
led to almost complete microglial elimination (97–100% reduc-
tion; Fig. 3c and quantified in e and f), even with 24 weeks of
treatment, showing that PLX5622 allows for extended elimination
of microglia. The absence of microglia for 24 weeks in wild-type
mice did not induce any measurable negative effects in
animal behavior, including tests of anxiety (elevated plus maze;
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Fig. 1 Plaque-distal microglia contain aggregated Aβ. a–e 15-month-old 3xTg-AD mice were stained for dense core deposits with Thio-S (in green), and
immunolabeled for microglia (IBA1 in red) and macrophage lysosomes (CD68 in blue; a, c, and e) with zoomed image (b) of Thio-S+ material within
microglia and within lysosomes, separately. Scale bars= 20 μm for a, e 5 μm for b, 10 μm for c. d, f Three-dimensional reconstruction of microglia (IBA1 in
red), the microglial lysosome (CD68 in purple), and fibrillar Aβ (Thio-S in green), demonstrating the localization of Aβ to the microglial lysosome in non-
plaque associated microglia. Scale bars= 7 μm. g–j 5xFAD animals stained for dense-core deposits (Thio-S in green) and immunolabeled for microglia
(IBA1 in red; g and i), with zoomed images (h, j) demonstrating Thio-S+ aggregates in microglial cell bodies in 4- and 7-month-old 5xFAD mice. Scale
bars= 40 μm for g, i 10 μm for h, j
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Fig. 3g, h) and motor-function (open field; Supplementary
Figure 3A–D). Compared to wild-type animals, 5xFAD mice
showed reduced anxiety-related behaviors compared to controls
in the elevated plus maze (EPM; Fig. 3g, h). We previously
reported reduced EPM anxiety-related behavior in a model of
hippocampal neuronal lesion18, suggesting that hippocampal
functioning in 5xFAD animals at this age may be impaired. With
microglial elimination, these behaviors were further exacerbated
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(Fig. 3g, h). To assess hippocampal-dependent memory, mice
underwent testing using Y-Maze, Morris water maze (MWM),
and Contextual fear conditioning (CFC) and 5xFAD animals did
not show impairments in any of these tasks (Supplementary
Figure 3E–G; Fig. 3i–k). In the MWM probe trial, PLX5622-
treated wild-type mice tended to spend more time in the platform
zone compared to wild-type mice (Fig. 3k), indicating that the
long-term absence of microglia is not detrimental to murine
cognitive function and may be beneficial, at least in this assay,
which is consistent with our prior findings17,18.
Microglial elimination impairs plaque formation. Having
demonstrated robust microglial elimination prior to and
throughout the period of plaque formation in 5xFAD mice, we
next sought to determine the consequences of microglial ablation
on pathology. In wild-type mice, CSF1R inhibitor treatment for
10 weeks eliminated > 99% of microglia in the cortex (Fig. 4a–f),
but a fraction of cells remained in the thalamus (Fig. 4i; enlarged
in Supplementary Figure 4). Treatment of 5xFAD mice with
PLX5622 again reduced > 99% of microglia in the cortex (Fig. 4d,
g), but as noted in wild-type mice, a fraction of cells remained in
the thalamus (Fig. 4j). In the absence of microglia, we observed a
stark lack of dense-core plaques within cortical regions (quanti-
fied in Fig. 4l; retrosplenial (RS) and somatosensory (SS) cortices
examined). Notably, a band of plaques were found in the RS
cortex, but these were primarily associated with microglia that
had survived treatment (Fig. 4d). Plaques were also formed within
the thalamus but were again predominantly associated with
surviving microglia (Fig. 4j). Close examination of the Thioflavin-
S (Thio-S) stained slices revealed deposits beginning to form
within cortical blood vessels (Fig. 4d, g – yellow arrows). These
results suggest that microglia may be critical regulators of plaque
formation and that few surviving microglial cells are sufficient to
facilitate some degree of plaque formation (i.e., as seen in the
thalamus).
Consistent with the 10-week treated 5xFAD mice, examination
of pathology in the 24 week treated mice revealed diminished
Thio-S+ dense-core plaque numbers in the cortices of the 5xFAD
mice devoid of microglia (Fig. 4e, h; quantified in M). In the 10-
week treated cohort, we noted the appearance of plaques in areas
that exhibited small populations of surviving microglia (RS cortex
and thalamus; Fig. 4d, j). With an additional 14 weeks of
treatment (i.e., 24 weeks treated animals), microglia were
eliminated brain wide (Fig. 4e, k), but Thio-S plaques persisted
in these areas (i.e., the thalamus and RS cortex). Average plaque
volumes were ~30–40% smaller, across many brain regions
(Fig. 4n), suggesting that microglia contribute to plaque growth in
the 5xFAD brain. Thus, even with increased treatment duration
to 7 months of age, plaque formation is prevented in the absence
of microglia.
Astrocytes surrounding plaques in the cortex of 7-month-old
5xFAD mice appeared activated, as assessed by GFAP immunor-
eactivity, which usually is absent in the cortex of non-diseased
brains (Supplementary Figure 5A–B). In contrast, GFAP expres-
sion was sharply reduced in 5xFAD mice devoid of microglia
(Supplementary Figure 5A–C). Absolute numbers of astrocytes
were not highly affected by pathology or microglial depletion, as
measured by S100β+ cells (quantified in Supplementary Fig-
ure 5D), except for a small increase in the RS cortex in 5xFAD
mice. These data suggest that microglia regulate astrocyte
reactivity in disease, fully consistent with previous reports19,20.
Notably, abundant Thio-S staining was discovered within large
cortical blood vessels in the 5xFAD mice devoid of microglia (i.e.,
Fig. 4e, h), indicative of cerebral amyloid angiopathy (CAA).
Hemisphere stitches of Thio-S staining show clear vascular
pathology in microglia-depleted 5xFAD mice (Fig. 4b). The
appearance of CAA occurred only in microglia-depleted 5xFAD
mice, as CAA was not observed in untreated 5xFAD mice or in
treated wild-type mice. In addition to Thio-S, CAA and plaques
stained postiviely for Aβ fibrils, via the conformation specific
antibody OC21 (Fig. 4r; Supplementary Figure 6C–D) and Aβ42
(Fig. 4s; Supplementary Figure 6E–F), but were negative for Aβ
oligomers via A11 antibody22 (Fig. 4q; Supplementary
Figure 6A–B). Staining for pyroglutamate-3 Aβ, which forms
the plaque cores23, revealed a sharp reduction in immunor-
eactivity in PLX5622-treated 5xFAD mice in the cortex (Fig. 4p;
Supplementary Figure 6G–H), along with reductions in 6E10+
diffuse plaques (Fig. 4o; Supplementary Figure 6G–H). Of note,
pyroglutamate-3 immunoreactivity was found in areas of treated
5xFAD mice that exhibited plaque pathology (i.e., thalamus;
Supplementary Figure 6I–J).
As blood vessel accumulation of Aβ is known to increase the
risk of intracranial hemorrhage and hemorrhagic stroke in
human brains24, we wanted to evaluate whether similar
pathology was developing in microglia-depleted 5xFAD ani-
mals. Examination for microbleeds in 4- (Supplementary
Figure 7A–D) and 7- (Supplementary Figure 7E–H) month
cohorts of mice revealed notable iron deposits in the thalamus
of four treated 5xFAD mice (2 animals/cohort). While
surprising to find strong thalamic microbleeds in a subset of
treated 5xFAD mice, transgenic AD animals that develop
primarily CAA and exhibit extensive Aβ deposition in thalamic
microvasculature also show an increase in thalamic micro-
bleeds25, highlighting the susceptibility of this region to develop
vascular-related impairments/dysfunction. Immunolabeling
for the endothelial tight junction marker, Claudin-5, revealed
an increase in Thio-S positive blood vessel diameter
Fig. 2 Design and synthesis schematic of the CSF1R inhibitor PLX5622 for extended microglial elimination. a Chemical structure of selective CSF1R inhibitor
PLX5622. PLX5622 is structurally similar to CSF1R/KIT/FLT3 inhibitor PLX3397 with modifications concentrated on the two pyridine moieties. b X-ray
crystal structure of the CSF1R-PLX5622 complex. PLX5622 is anchored to the active site of CSF1R by 3 hydrogen bonds (indicated by dashed lines). 7-
Azaindole of PLX5622 forms two hydrogen bonds with the hinge region of CSF1R whereas the central pyridine ring forms a hydrogen bond with the main
chain amino group of Phe796. The CSF1R selectivity is largely determined by the interaction between PLX5622 and Gly795 (represented as a sphere),
which is a bulkier residue (cysteine) in KIT and FLT3. The substitutions on the tail pyridine ring also contribute to the selectivity. This group displaces the
juxatemembrane (JM) region (absent in the structure) from the allosteric site. In contrast, PLX3397 binds CSF1R in the presence of the JM region.
c Synthesis schematic for PLX5622 and subsequent formation of PLX5622-fumaric acid salt. PLX5622 was synthesized from commercially available 2-
amino-6-fluoropyridine (1), 5-fluoro-2-methoxypyridine-3-carbaldehyde (2), and 3-iodo-5-methyl-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (7) using
the reaction scheme. d Immunolabeling of microglia (IBA1 in green) and cell nuclei (DAPI in blue) of two-month-old animals treated with control or 1200
ppm PLX5622-formulated chow. Scale bar= 75 μm. E, Quantification of hippocampal microglial number over 5 days of treatment with PLX5622 (p < 0.001
for 3d and 5d). Two-way ANOVA with Dunnet’s post hoc test. n= 3 for Control, n= 3 for 3d PLX5622, n= 3 for 5d PLX5622. Statistical significance is
denoted by ***p < 0.001. Error bars indicate SEM
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(Supplementary Figure 7I–K), consistent with prior data26, and
reduced intensity of Claudin-5 staining in Aβ-associated blood
vessels (Supplementary Figure 7L), suggesting impaired vas-
cular integrity in the presence of Aβ pathology.
The absence of microglia did not significantly alter the levels of
Aβ38, Aβ40, or Aβ42, in detergent-soluble or -insoluble cortical
and thalamic homogenates in either the 4- or 7- month cohorts
(Fig. 5a–h), in line with multiple studies showing that CSF1R
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inhibition does not affect Aβ production/clearance10,27,28. Thus,
the absence of microglia modulates the location of Aβ
accumulation (i.e., parenchyma vs. vasculature) but does not
alter the net amounts present.
Investigations into oligomeric species of Aβ (via A11
immunoblotting) found no significant changes in protein levels
with microglia elimination in 5xFAD mice (Fig. 5i, j). To confirm
that APP processing was unchanged with microglia elimination
in 5xFAD mice at the protein level, we immunoblotted cortical
tissue for various components of the APP processing pathway
including APP and its cleavage products, as well as proteins
associated with α- (ADAM10), β- (BACE1), and γ- (PEN2 and
PS1) secretase activity. We found significant elevations in full-
length (fl) APP and Carboxy-terminal fragments of APP (C99
and C83) in 5xFAD mice relative to wild-type (Fig. 5k, l), but
observed no reductions in protein levels with PLX5622 treatment
in 5xFAD animals. Additionally, gene expression analyses of AD-
related genes were performed (Fig. 5m; methods described in
greater detail for Figs 8, 9) and we found minimal changes with
microglia depletion, other than in microglial expressed genes (i.e.,
Trem2, Spi1, Inpp5d, and Ctsd).
Microglial plaque compaction ameliorates neuritic dystrophy.
Upon examining caudal brain regions, we found some IBA1+
cells present within the subiculum and associated white matter
tracts in the otherwise microglia-devoid 5xFAD animals (mice
treated through 1.5–7 months of age; Fig. 6a, b). While PLX5622
treatment reduced myeloid cell numbers in the subiculum (77%
reduction; Fig. 6e), we observed a tight spatial association
between surviving cells and Thio-S plaques (Fig. 6b, d), similar to
that seen in the thalamus of the 10-week treated 5xFAD mice
(Fig. 4j). In fact, plaques were predominantly observed in the
immediate vicinity of surviving IBA1+ cells – within the sub-
iculum and associated white matter tract – while the cortex
contained only vascular Thio-S+ deposits, in stark contrast to
untreated 5xFAD mice (Fig. 6a vs. b). Quantification of Thio-S+
subicular plaques revealed a 33% decrease in plaque number
(Fig. 6f) with PLX5622 treatment in 5xFAD mice. Importantly,
these results highlight a clear relationship between microglia/
myeloid cells and the appearance of plaques, suggesting a role of
microglia/myeloid cells in facilitating plaque formation, and
emphasizes that few cells are required for this process to occur.
Structural examination of the plaques that had formed in
PLX5622-treated 5xFAD mice (treated through 1.5–7 months of
age), presumably due to the presence of surviving microglia at the
time of their formation, revealed morphological differences
compared to plaques formed and maintained in the presence of
microglia (Fig. 6g–i). These plaques displayed an irregular shape
with structured filaments radiating out from a central fissure/
point and lacked the homogenous staining intensity of plaques in
microglia-intact 5xFAD mice. As such, both plaque circularity
(Fig. 6j) and mean Thio-S intensities (Fig. 6k) were reduced in the
5xFAD mice devoid of microglia. These features were common to
all areas explored, including in the subiculum, where some IBA1+
cells were still present, suggesting that some threshold density of
microglial cells may be required for full plaque compaction/
restructuring.
Focusing on plaque structure, we next evaluated the presence
of ApoE within plaque cores – previous reports describe the
coaggregation of ApoE with Aβ fibrils in both plaques and
vascular pathology29,30. Consistent with this, ApoE immunor-
eactivity was apparent within dense core plaques, but also in
cellular processes surrounding the cores (Fig. 6l). Colocalization
with the microglia/myeloid marker IBA1 revealed that these
ApoE positive processes were indeed microglia (Fig. 6l), con-
firming that plaque-associated microglia are a source of ApoE30.
Examination of ApoE immunoreactivity in microglia-devoid
5xFAD mice showed that the ApoE+ microglial processes
surrounding dense core plaques were absent, as expected, but
also the plaque cores themselves lacked ApoE staining (Fig. 6m).
We quantified ApoE immunoreactivity in Thio-S dense core
plaques in the cortex and thalamus, revealing a ~50–70%
reduction in core ApoE (Fig. 6n). Thus, microglia surrounding
plaques are a major source of plaque-associated ApoE, supporting
recent findings30,31.
Dystrophic neurites are found in a halo around fibrillar
plaques and are characterized by the accumulation of LAMP1 and
APP32–34. To evaluate the role of microglia in regulating the
growth of dystrophic neurites, we stained for LAMP1 (Fig. 6o)
and APP (Fig. 6q) and found that the absence of microglia
enhanced the dystrophic neurite halo area (Fig. 6p, r). These
results are consistent with prior studies showing that microglia
form a physical barrier around plaques and compact Aβ into
dense deposits, protecting against local neurite damage35–37.
Alternative CSF1R inhibitor confirms diminished plaque load.
Given the striking effects of PLX5622 treatment/microglial
depletion on reducing plaque formation, we wanted to confirm
the results with alternative CSF1R inhibitor paradigms. We
established that PLX3397 formulated at 600 ppm in chow could
Fig. 3 Extended elimination of microglia does not induce peripheral leukocyte or behavioral abnormalities. 1.5-month-old wild-type (WT) or 5xFAD mice
were treated with control chow or PLX5622 for 10 or 24 weeks. a Experimental design. b Terminal PK of PLX5622 and 5xFAD+ PLX5622 groups. Two-
tailed independent t-test. n= 5–6 for PLX5622, n= 8–11 for 5xFAD+ PLX5622. c Hemisphere stitches of microglia (IBA1 in green) in the 7-month-old
cohort. Scale bar= 1000 μm. d Analysis of different subsets of leukocytes (CD11b, p= 0.059; CD19, p= 0.052; all others NS). Two-tailed independent
t-test; n= 4–5 for Wild-type, n= 3–4 for PLX5622. e–f All analyses listed in respective order for retrosplenial (RS) cortex, somatosensory (SS) cortex, and
thalamus. Microglial number in 4 e and 7 f month-old cohorts (4-month cohort: WT v 5xFAD, p= 0.001, NS, p < 0.001; WT v PLX5622, p < 0.001, p <
0.001, p= 0.044; 5xFAD v 5xFAD+ PLX5622, p < 0.001, p < 0.001, p < 0.001. 7-month cohort: WT v 5xFAD, p= 0.015, p= 0.024, p < 0.001; WT
v PLX5622, p < 0.001 for all regions; 5xFAD v 5xFAD+ PLX5622, p < 0.001 for all regions). Two-way ANOVA with Tukey’s post hoc test; n= 4–6 for Wild-
type, n= 4–6 for PLX5622, n= 5–8 for 5xFAD, n= 6–9 for 5xFAD+ PLX5622. g–h Measurements for anxiety were performed by Elevated Plus Maze
(EPM) and quantified as number of arm entries (g WT v 5xFAD, NS (open) and p= 0.050 (closed); PLX5622 v 5xFAD+ PLX5622, p= 0.007 (open) and
p < 0.001 (closed), 5xFAD v 5xFAD+ PL5622, NS (open) and p= 0.056 (closed)) and time in arms (h WT v 5xFAD, p= 0.0157 (open) and p= 0.046
(closed); PLX5622 v 5xFAD+ PLX5622, p < 0.001 (open) and p < 0.001 (closed); 5xFAD v 5xFAD+ PLX5622, p < 0.001 (open), p < 0.020 (closed)).
i Mean latencies to a hidden platform from the Morris water maze (MWM) acquisition trials. j–k Number of platform entries (j; PLX5622 v 5xFAD+
PLX5622, p= 0.071) and time in platform zone (k; WT v PLX5622, p= 0.094; PLX5622 v 5xFAD+ PLX5622, p= 0.073) in the MWM probe trial. For all
behavioral analyses: Two-way ANOVA with Tukey’s post hoc test; n= 8–12 for Wild-type, n= 8–12 for PLX5622, n= 9–12 for 5xFAD, n= 8–9 for 5xFAD
+ PLX5622. Statistical significance is denoted by *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical trends are denoted by #p < 0.10. NS, not significant (p >
0.10). Error bars indicate SEM
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achieve robust brain-wide microglial elimination ( > 99%)38, and
thus, treated 1.5-month-old 5xFAD mice with this formulation
until 5 months of age (Fig. 7a). Again, examination of the brains
of these treated mice showed minimal plaque pathology and the
appearance of CAA (Fig. 7c, d – zoomed image of CAA in D). We
further examined the role of peripheral CSF1R inhibition on AD
pathology by treating 1.5-month-old 5xFAD mice until 5 months
of age with PLX3397 (75 ppm) chow (Fig. 7a) – a formulation
that provides robust peripheral CSF1R inhibition without
microglial elimination17. This lower dose achieved brain levels of
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~1 μM, compared to ~10 μM with the higher dose (Fig. 7b), and
accordingly, microglia numbers were unchanged relative to
untreated animals (Fig. 7e–i). With 75 ppm PLX3397, no
reductions in plaque load or appearance of CAA were detected in
treated 5xFAD animals compared to controls (Fig. 7f, h, j–k).
Thus, peripheral CSF1R inhibition or simply the presence of
CSF1R inhibitor within the CNS do not attribute to the reduc-
tions in plaque pathology and more complete microglial elim-
ination is necessary to perturb plaque formation processes.
Gene expression analyses across three brain regions. Given the
prolonged absence of microglia throughout the adult life of
CSF1R-inhibitor-treated wild-type and 5xFAD mice, the stark
reduction in plaque formation in the absence of microglia, and
the differences in pathology deposition and microglial number in
various brain regions (i.e., no plaques but CAA in cortex, plaques
but no microglia in thalamus and hippocampus/subiculum), we
explored alterations in regional gene expression (mice treated
through 1.5–7 months of age). To that end, brains were micro-
dissected into cortical, hippocampal, and thalamic+ striatal
regions. RNA was extracted, and subsequently analyzed by RNA-
seq (n= 4/group; Principle Component Analyses shown in
Supplementary Figure 8).
Extensive microgliosis across all brain regions in 5xFAD mice:
To assess the global effects of pathology on gene expression, we
compiled a list of genes significantly changed (using raw p-values)
in all 3 brain regions in 5xFAD vs. wild-type mice (Fig. 8a). All
common genes were upregulated and the vast majority are
microglia-associated, reflecting the microgliosis occurring in
5xFAD mice. The elevation levels averaged 1-fold-change higher
across all homeostatic microglial genes, consistent with the
observed increase in microglial numbers (Fig. 3f). Consistent with
these genes being predominantly expressed by microglia, their
expression was markedly reduced with treatment in either 5xFAD
or wild-type mice. We selected a subset of homeostatic microglial
genes (Csf1r, Cx3cr1, C1qa, Hexb, Siglech, and Spi1) and displayed
the expression (RPKM) values for each of the brain regions
(Fig. 8b). The expression of these genes was nearly undetectable
from PLX5622-treated mice, highlighting their specific expression
by microglia and the specificity of PLX5622 on microglial
survival. Of note, the expression of homeostatic microglial genes
was higher in the 5xFAD+ PLX5622 hippocampus than other
microdissected brain regions (or wild-type mice), reflecting the
population of surviving microglia identified in the subiculum
(Fig. 6d). Next, we sought to characterize the gene expression
profile of the surviving, plaque-forming microglia in treated
5xFAD animals. To that end, we searched for genes upregulated
in 5xFAD brains that were subsequently downregulated with
PLX5622 treatment (to select for microglia-expressed genes) but
not present in wild-type brains. We identified expression of Ccl6,
Clec7a, Cst7, Ctsd, Ctsz, and Itgax as main genes that follow this
expression pattern (Fig. 8c), as well as Asb10, B2m, Ccl3, Ch25h,
Gpr65, Grn, Hcar2, Hexa, Ly9, Lyz2, Oasl2, Pdcd1, Plcg2, and
Treml2. Notably, several of these genes are known markers of
disease-associated microglia39 (DAM). Consistent with our
expectations, we detected expression of many of these genes
(i.e., Ccl6, Clec7a, and Cst7) in PLX5622-treated 5xFAD
hippocampi (but not cortex or thalamus), reflecting the
population of surviving microglia in this region (see images of
subicula in Fig. 6c–d, which are included in microdissected
hippocampi) and providing a gene expression signature of
plaque-forming/associated microglia.
Microglial depletion prevents the downregulation of synaptic
genes in the hippocampus: We compared the number of
differentially expressed genes (adjusted p-values < 0.05) induced
by AD pathology in each of the three microdissected brain
regions (i.e., wild-type vs. 5xFAD) and found that the
hippocampus was most impacted (413 genes), while both cortex
and thalamus exhibited fewer changes in gene expression (141
and 107 genes respectively; Fig. 9a). Transgene expression in
5xFAD mice (consisting of App, Psen1, and Thy1) was increased
by ~2-fold over endogenous expression across brain regions
(Fig. 9b) and was not impacted by treatment, consistent with the
protein expression data (Fig. 5k, l). Initially focusing on the 413
gene expression changes in the hippocampus induced by
pathology, we plotted a heat map of the log(2) fold change for
each of the 9 relevant comparisons (5xFAD vs. wild-type,
5xFAD+ PLX5622 vs. 5xFAD, and PLX5622 vs. wild-type, each
for cortex, hippocampus, and thalamus; Fig. 9c). The hippocam-
pus displayed a unique gene expression profile relative to the
cortex and thalamus and included a unique subset of down-
regulated genes. Of note, only 1 downregulated gene was
identified in the cortex and none were detected in the thalamus.
Furthermore, all gene expression changes (either upregulated or
downregulated) appeared to be fully reversed in the hippocampus
of treated 5xFAD mice, with fold-changes in 5xFAD+ PLX5622
vs. 5xFAD hippocampus being equal and opposite to those
induced in the 5xFAD mice (highlighted by red border). Of the
413 identified genes, 77 were downregulated in the 5xFAD
hippocampus (Fig. 9c, and individual genes plotted in D).
Notably, these transcripts were primarily synaptic and neuronal
in nature, including genes such as Dlk2, Dync1l1, Gls, Kcnq3,
Nrg3, and Scn1b. In the absence of microglia, this disease-
associated downregulation of neuronal and synaptic genes was
prevented (Fig. 9e), highlighting the detrimental role microglia
may have on hippocampal plasticity in the 5xFAD brain.
Fig. 4 Long-term elimination of microglia in 5xFAD mice reduces plaque number and volume and is accompanied by cerebral amyloid angiopathy (CAA)
onset. All analyses listed in respective order for retrosplenial (RS) cortex, somatosensory (SS) cortex, and thalamus. a Representative hemisphere stitches
of dense-core deposits (Thioflavin-S (Thio-S) in green) and microglia (IBA1 in red). Scale bar= 1000 μm. b Representative images of brain hemispheres
stained with Thio-S, illustrating the appearance of cerebral amyloid angiopathy (CAA) throughout the cortex of 5xFAD mice devoid of microglia. Scale
bar= 1000 μm. c–d, f, g, i, j Confocal images of sections from 10 week treated animals stained for dense-core plaques (Thio-S in green) and
immunolabeled for microglia (IBA1 in red). Scale bar= 100 μm. e, h, k Images from 24 week treated animals stained for dense-core plaques (Thio-S in
green) and immunolabeled for microglia (IBA1 in red) and diffuse plaques (6E10 in blue). Scale bar= 100 μm. l, Quantification of Thio-S plaque number in
4-month-old cohort (p < 0.001, p < 0.001, p= 0.001). Two-tailed independent t-test; n= 7 for 5xFAD, n= 8 for 5xFAD+ PLX5622. m Quantification of
Thio-S+ plaque number in 7-month-old mice (p= 0.001, p= 0.004, p= 0.041). Two-tailed independent t-test; n= 7–8 for 5xFAD, n= 5–6 for 5xFAD+
PLX5622. N, Plaque volumes in 7-month-old mice (p= 0.003, NS, p= 0.007). Two-tailed independent t-test; n= 7–8 for 5xFAD, n= 5–6 for 5xFAD+
PLX5622. O-P, Quantification of 6E10 (p= 0.002) and pyroglutamate-3-modified Aβ (p= 0.008) in the cortex of 7-month-old animals. Two-tailed
independent t-test; n= 4–5 for 5xFAD, n= 4–5 for 5xFAD+ PLX5622. q–s, 7-month-old PLX5622-treated 5xFAD animals stained for dense core deposits
(Thio-S in green) and immunolabeled for oligomeric Aβ (A11), protofibrillar Aβ (OC) and Aβ1−42, respectively. Scale bar= 25 μm. Statistical significance is
denoted by *p < 0.05, **p < 0.01, and ***p < 0.001. NS, not significant (p > 0.10). Error bars indicate SEM
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Enrichment analyses of the hippocampus revealed an upregula-
tion in immune function-associated pathways in 5xFAD vs. wild-
type, and accordingly, these pathways were all highly significantly
downregulated with PLX5622 treatment (Fig. 9f). Analyses of
downregulated pathways in 5xFAD vs. wild-type hippocampi
revealed that the most highly significant pathways were related to
neuronal functioning, such as glutamate receptors, synaptic
vesicles, and neuronal membranes (Fig. 9f). Importantly, many
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of these pathways were upregulated – or more accurately, never
downregulated – with the absence of microglia (Fig. 9f),
indicating that microglia influence neuronal gene expression
pathways in response to AD pathology. To confirm these gene
expression results, we measured gene expression levels from wild-
type, PLX5622, 5xFAD, and 5xFAD+ PLX5622 hippocampal
RNA using a Nanostring Neuropathology panel. Accordingly,
overlapping microglia genes were increased and neuronal genes
decreased in 5xFAD mice compared to wild-type mice, which did
not occur with PLX5622 treatment (Supplementary Figure 9).
Neither modulation of AD pathology nor microglial number
grossly alter AD-related gene expression: Although we confirmed
that the absence of microglia/treatment with PLX5622 did not
alter the amount of Aβ produced, we wanted to explore the
impact of pathology and microglia on genes associated with APP
processing, Aβ clearance and metabolism, and AD in general
(Fig. 5m). The only significant changes in gene expression in
5xFAD mice compared to wild-type were the upregulation of the
transgenes (App and Psen1; as expected due to overexpression),
and Apoe, all of which were not altered by the absence of
microglia, and the downregulation of myeloid-expressed Trem2,
Ctsb, Ctsc, and Ctsd in the absence of microglia, as expected.
Comparisons of changes in expression between brain regions
showed regional differences in Ache, Apoe, Ptk2b, Sorl1, and
Sort1. Thus, both AD pathology and the absence of microglia
have minimal effects on AD-related genes, and importantly, we
observe no alterations in gene expression or protein production in
the absence of microglia that could account for reduced plaque
formation.
Microglial repopulation seeds plaques. While microglia can be
indefinitely depleted via the continued administration of CSF1R
inhibitors, the microglial compartment can also be repopulated
upon CSF1R inhibitor withdrawal17,40,41. To further prove that
microglia are responsible for plaque formation, we sought to
examine the effects of microglial repopulation in 5xFAD mice
after 10 weeks of PLX5622 treatment. We treated a cohort of 1.5-
month-old 5xFAD mice with PLX5622 (1200 ppm in chow) to
eliminate microglia until 4 months of age, then CSF1R inhibitor-
formulated chow was removed to stimulate microglial repopula-
tion and the brains were examined one month later (Fig. 10a).
Microglia repopulated all areas of the brain in both wild-type and
5xFAD mice (Fig. 10b), although overall densities were lower
than the untreated mice in cortical regions (Fig. 10c, d; quantified
in F). As demonstrated previously, untreated 5xFAD mice exhibit
cortical plaques at 4 months of age, but 5xFAD mice devoid of
microglia show reduced plaque formation (Fig. 4d, g, l). Fur-
thermore, from our extended cohort of 5xFAD mice devoid of
microglia, we know that plaque formation is severely diminished
in treated 5xFAD animals, even by 7 months of age (Fig. 4e, h,
m). However, examination of microglia-repopulated 5xFAD
brains revealed the appearance of robust plaque pathology
(Fig. 10d) with plaque numbers being equal to the untreated
5xFAD mice (Fig. 10g), although average plaque volumes were
smaller (Fig. 10h). Notably, vascular pathology was still present in
the repopulated brains (Fig. 10d), showing that the reintroduction
of microglia does not reverse the vascular deposition of Aβ, at
least within this one-month timeframe. Repopulating microglia
associate with the new plaques but do not appear to react to the
vascular deposits (Fig. 10e). Moreover, GFAP+ astrocytes asso-
ciated with plaques in both control and repopulated 5xFAD
brains (Fig. 10i, j), but were absent in 5xFAD brains devoid of
microglia. Thus, the reintroduction of microglia in the 5xFAD
brain via CSF1R inhibitor withdrawal coincides with a full
restoration of plaque pathology and implicate the reappearance of
microglia in the brain with the seeding and formation of plaques.
Discussion
In this study, we sought to investigate the role of microglia
throughout the onset and development of AD pathology in
5xFAD mice via the sustained depletion of microglia from the
adult mouse brain for a period of ~6 months. While various
methods of microglial ablation are available, the extent/duration
of microglial depletion and the technical requirements necessary
to achieve sustained microglial elimination prohibit the use of
most depletion paradigms. For example, the
CX3CR1creERxDTRff mouse model relies on administration of
diphtheria toxin, which not only induces a cytokine storm, but
also limits microglial elimination to 5 days41,42. The CD11b-
HSVTK model requires intracerebroventricular infusion of gan-
ciclovir in order to produce substantial microglial depletion,
which in turn induces BBB damage and myelotoxicity, resulting
in increased mortality following 4 weeks of ganciclovir treat-
ment11. Additionally, clodronate liposomes can be administered
to deplete microglia; however, this effect is short-lived and
requires intrahippocampal infusion, as clodronate liposomes are
incapable of crossing the BBB43. Previously, we discovered that
microglia are critically dependent upon CSF1R signaling for their
survival17 and that CSF1R inhibitors serve as effective tools to
achieve microglial depletion. In contrast to other methods, CSF1R
inhibitor-induced microglial depletion is advantageous due to its
(1) non-invasive route of administration, (2) independence from
pharmacological drivers such as ganciclovir or tamoxifen, (3) lack
of an inflammatory response (i.e., cytokine storm) from surviving
cells, (4) highly selective effects on the microglial compartment,
(5) modifiable formulation, allowing for investigations into the
contribution of peripheral myeloid populations on microglial
responses, and (6) clinical utility, facilitating the translation of
Fig. 5 No detectable alterations in Aβ levels or APP processing with microglia elimination in 5xFAD mice. a–h Aβ levels from cortical (a–b, e–f) or thalamic
brain homogenates (c–d, g–h) from 5xFAD mice treated with vehicle or PLX5622 (1200 ppm in chow) from 1.5 months of age to either 4 (a–d), or 7 (e–h)
months of age, for both the detergent-soluble and insoluble fractions. In the 4-month-old mice, insoluble Aβ1–38 and Aβ1–40 were below detection threshold.
In the 7-month-old mice, insoluble Aβ levels were plotted on log(10) scale and insoluble Aβ1–38 was below detection threshold. Two-tailed independent t-
test. For 4-month-old cohort: n= 7 for 5xFAD, n= 9 for 5xFAD+ PLX5622. For 7-month-old cohort: n= 7 for 5xFAD, n= 8 for 5xFAD+ PLX5622. i–j
Cortical homogenates of 7-month-old mice immunoprobed and quantified, respectively, for A11. Two-tailed independent t-test; n= 7 for 5xFAD, n= 8 for
5xFAD+ PLX5622. Source data are provided as a Source Data file. k–l Levels of components of the amyloid-precursor protein (APP) processing pathway in
cortical homogenates from 7-month-old animals (Full length APP: WT v 5xFAD, p= 0.001; PLX5622 v 5xFAD v PLX5622, p < 0.001; 5xFAD v 5xFAD+
PLX5622; p= 0.020. C83: WT v 5xFAD, p < 0.001; PLX5622 v 5xFAD v PLX5622, p < 0.001. C99: WT v 5xFAD, p= 0.015; PLX5622 v 5xFAD v PLX5622
p < 0.001). Two-way ANOVA with Tukey’s post hoc test; n= 8 for Wild-type, n= 8 for PLX5622, n= 8 for 5xFAD, n= 8 for 5xFAD+ PLX5622. Source
data are provided as a Source Data file. M, Left panel - heatmap of log(2) fold change of genes associated with AD, including APP/Aβ production and
metabolism shown for each of the 9 comparisons and the 6 comparisons between brain regions. Right panel – heatmap of the corresponding p-values for
each of the comparisons. Log(2) fold change and p-values indicated by respective scale bar. n= 4 for all groups. Error bars indicate SEM
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experimental findings. Most importantly, CSF1R inhibition is the
only currently available method capable of achieving sustained
long-term microglial elimination. Here, we sought to optimize a
CSF1R inhibitor regimen to eliminate microglia brain-wide and
maintain the absence of microglia for an unprecedented 6-month
treatment duration. To that end, we designed and created
PLX5622, which shows high selectivity for the CSF1R (Supple-
mentary Table 2), desirable PK characteristics across species
(mouse, rat, dog, monkey; Supplementary Table 5) including oral
bioavailability, a > 20% brain penetrance (Supplementary
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Table 6), and rapid/sustained elimination of microglia (Figs 2, 3).
Using PLX5622, we were able to eliminate > 95% of microglia
from the brains of 5xFAD mice prior to and during the formation
of AD pathology – a treatment duration of up to 6 months - and
elucidate their roles in plaque formation. Data presented here
show that long-term PLX5622-mediated microglial depletion is
highly robust, sustainable, and specific to the microglial com-
partment. These findings are demonstrated by extensive gene
expression analyses, a lack of behavioral/cognitive impairments,
and unaffected number of circulating immune cells. Together,
these data demonstrate that PLX5622 is a useful compound for
investigating microglial dynamics. Of note, loss of function
mutations in the tyrosine kinase domain of the Csf1r are asso-
ciated with the development of adult-onset leukoencephalopathy
with axonal spheroids and pigmented glia44, the onset of which is
thought to derive from microglial phenotypic alterations45.
However, we find here that long-term CSF1R inhibition (and
consequential microglial loss) do not recapitulate these disease
phenotypes, suggesting that the loss of a single CSF1R allele exerts
different effects on the brain microenvironment relative to the
loss of microglia.
The genetics of familial AD indicate that altered APP proces-
sing and plaque accumulation are critical for disease etiology46. In
sporadic AD, plaques appear in the brain prior to any other overt
pathologies1 and precede cognitive deterioration and disease
progression47–49. AD appears to be precipitated by the formation
and development of plaques in the brain, and therefore, identi-
fying the underlying biology of plaque formation is crucial to
understanding and preventing disease onset. Genome-wide
association studies have identified several genes associated with
an increased risk for developing sporadic AD. Many of these risk
variants are highly enriched in myeloid cells3, indicating that
myeloid biology appears to be a large contributor to the devel-
opment of disease. Microglia are the resident myeloid cell of the
CNS, and their activated presence surrounding plaques is a
prominent feature of AD pathology. While microglia are pha-
gocytes, in the later stages of disease, studies indicate that these
cells do not clear Aβ or modulate plaque numbers/sizes in the
brain10–12. Instead, evidence indicates that they play a role in
synaptic damage and neuronal loss10,49–51. Examination of
human brains (non-demented, high pathology non-demented,
and Alzheimer’s disease subjects), as well as mouse models of AD,
reveal the accumulation of Aβ aggregates within the lysosomes of
microglia unassociated with plaques. Thus, we hypothesized that
neuronally-derived Aβ is internalized/aggregated within micro-
glia, and that this material contributes to the initial formation of
plaques. In a prior study we explored the roles of microglia in the
later stages of AD, by eliminating microglia at a time point at
which 5xFAD mice had already developed extensive plaque
pathologies. We found that the elimination of microglia conse-
quently prevented the synaptic and neuronal loss, without
affecting plaque loads10, with subsequent studies confirming the
contribution of microglia to neuronal loss52,53. In this study, we
sought to identify whether microglia play a role in the initial
deposition of plaques, via sustained treatment with PLX5622
prior to and during the period of plaque formation in the 5xFAD
mouse model of AD. Here, we find that plaque formation is
prevented in the absence of microglia, even over extended periods
of time. While some plaques form in specific brain areas with
treatment, we find that these few remaining plaques are asso-
ciated with a small subset of microglia initially resistant to
CSF1R-inhibition. These microglia are most apparent in the
thalamus, retrosplenial cortex, and subiculum. Once formed,
these plaques persist thereafter, even long after plaque-associated
microglia are eliminated. Thus, our results demonstrate that
plaque onset relies on the presence and activity of microglia.
Additionally, as some microglia survive CSF1R inhibitor treat-
ment, this approach also allows for the exploration of these
remaining cells in the maintenance of plaque structure. Insights
into the roles of microglia in plaque biology have been explored
via the study of the myeloid cell-expressed gene Trem2, in which
coding mutations thought to be loss of function are associated
with increased risk of sporadic AD54–56. Recently, it was
demonstrated that perturbation of TREM2 signaling impaired the
association of microglia with plaques36,37,57, revealing that
plaque-associated microglia compact plaque cores and form a
barrier that protects surrounding neurites from toxicity35–37. In
line with these studies, we confirm and demonstrate that plaque
compaction and barrier formation are natural functions of
microglia in disease, rather than functions conferred by the loss of
TREM2. In addition, we show that microglia are necessary for the
development of plaques - these findings are supported by recent
data showing that plaque seeding is accelerated in Trem2
knockout mice30, suggesting that microglial functions involved in
the initial formation of plaques are related to TREM2 signaling.
Collectively, these studies point to a role of microglia in plaque
development, which is supported by our current findings.
By way of mechanism for plaque seeding and growth, microglia
could be: (1) secreting factors that facilitate Aβ fibrillization58, (2)
physically forming plaque cores from extracellular Aβ via com-
paction59, or (3) ingesting, aggregating, and modifying extra-
cellular Aβ internally, which is eventually released to seed
plaques, in line with in vitro data60. Indeed, low concentrations of
Aβ can be taken up by cells and concentrated into acidic vesicles,
yielding favorable conditions for the spontaneous aggregation of
Aβ15. Moreover, excessive accumulation of Aβ within microglial
Fig. 6 Microglia facilitate plaque formation and compaction. a, b, Representative hemisphere stitches of 5xFAD and 5xFAD+ PLX5622 mice stained for
dense-core plaques (Thio-S in green) and immunolabeled for microglia (IBA1 in red). Scale bar= 1000 μm. c, d Confocal images of subicula stained with
Thio-S for dense core plaques (green) and immunolabeled with IBA1 for microglia (red) and 6E10 for diffuse plaques (blue). Scale bar= 75 μm.
e Quantification of IBA1+ cells in the subiculum (WT v 5xFAD, p < 0.001; WT v PLX5622, p < 0.001; PLX5622 v. 5xfAD+ PLX5622, p= 0.002; 5xFAD v
5xFAD+ PLX5622, p < 0.001). Two-way ANOVA with Tukey’s post hoc test; n= 7 for Wild-type, n= 6 for PLX5622, n= 6 for 5xFAD, n= 6 for 5xFAD+
PLX5622. f, Plaque number within the subiculum is reduced by 33% in 5xFAD+ PLX5622 mice compared to 5xFAD animals (p < 0.001). Two-tailed
independent t-test; n= 6 for 5xFAD, n= 6 for 5xFAD+ PLX5622. g–i Confocal images of dense-core plaques (Thio-S in green) and microglia (IBA1 in red)
in the cortex, thalamus, and subiculum, respectively, of both 5xFAD groups showing an alteration in plaque morphology with CSF1R inhibitor treatment.
Scale bar= 25 μm. Arrows point to zoomed images of dense-core plaques. Scale bar= 10 μm. j, k, Quantification of plaque circularity (j; 5xFAD v 5xFAD+
PLX5622, p < 0.001) and Thio-S fluorescence intensity (k; 5xFAD v 5xFAD+ PLX5622, p < 0.001). Two-tailed independent t-test; n= 6–7 for 5xFAD, n= 6
for 5xFAD+ PLX5622. l–m Representative images from 7-month-old cohort immunolabled for ApoE (in red) and microglia (IBA1 in green) and stained for
dense-core deposits (Thio-S in blue). Scale bar= 100 μm. n Quantification of ApoE immunoreactivity in plaque cores (cortex: p < 0.001; thalamus: p <
0.001). Two-tailed independent t-test; n= 7–10 for 5xFAD, n= 7 for 5xFAD+ PLX5622. o–r, Immunolabeling and quantification of LAMP1 (o, p; p=
0.020) and APP (q, r; p= 0.068). Two-tailed independent t-test; n= 5 for 5xFAD, n= 4–5 for 5xFAD+ PLX5622. Scale bar= 100 μm. Statistical
significance is denoted by *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical trends are denoted by #p < 0.10. Error bars indicate SEM
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lysosomes can induce cellular death, potentially contributing to
plaque expansion through the release of Aβ aggregates at the site
of microglial death59. Here, we observe aggregated Aβ within the
lysosome of ramified microglia distal to plaques in two different
mouse models of AD (Fig. 1), as well as the human brain (Sup-
plementary Figure 1). This observation is seemingly contrary to
the idea that the source of internalized microglial Aβ is plaque-
derived. In accordance, we find that plaque growth ceases in the
absence of microglia, consistent with recent data demonstrating
microglial cellular death as a contributor to plaque growth59,
suggesting a mechanism by which microglia deliver Aβ to the
plaque seed/core. These data could suggest that following the
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uptake of freely available Aβ, microglia subsequently deposit
aggregated Aβ into the extracellular space, thus contributing to
the formation of a plaque. Therefore, microglia appear to have
complex and contrasting roles within AD61, namely their facil-
itation of plaque formation, plaque growth, plaque compaction,
and neuronal damage.
To further delineate these roles, we performed gene expression
analyses of wild-type and 5xFAD mice in cortex, hippocampus,
and thalamus, in both microglia-intact animals and mice lacking
microglia for the entirety of their adult lives. Notably, we find
hippocampal gene expression is greatly influenced by the presence
of AD pathology relative to the cortex and thalamus, despite
abundant plaque load in all these regions. RNA-seq analysis
revealed that nearly all significantly altered genes, in 5xFAD
compared to WT mice, were associated with microgliosis in the
cortex and thalamus, while the hippocampus displayed reductions
in gene expression associated with neuronal and synaptic function.
The absence of microglia prevented many of these changes in
5xFAD mice, despite the continued presence of hippocampal
plaques, due to a small population of surviving myeloid cells in the
subiculum. Although plaque-associated microglia may protect
against local neurite damage, the presence of microglia is also
required for the reduction in expression of synaptic and neuronal
genes in the hippocampus associated with AD. Notably, the
absence of microglia is associated with no alterations in immune-
and synapse-related genes, suggesting that microglia mediate most
AD pathology-induced changes in gene expression. Therefore,
microglia appear to have detrimental and beneficial roles in a
preclinical model of AD. Whether these effects are stratified into
separate populations (i.e., protective effects of plaque-associated
microglia vs. harmful effects of non-plaque associated microglia,
as recently suggested39) needs to be determined.
In conclusion, we have designed and created a specific CSF1R
inhibitor, PLX5622, that allows for the sustained and specific
elimination of microglia. This novel method of microglial depletion
provided us with the means to eliminate microglia for the duration
of AD pathogenesis. Ultimately, these data demonstrate that
microglial elimination is associated with the prevention of plaque
formation and the downregulation of hippocampal neuronal genes
that occur in a preclinical model of AD progression. These results
indicate that microglia appear to contribute to multiple facets of AD
etiology – microglia appear crucial to the initial appearance and
structure of plaques, and following plaque formation, promote a
chronic inflammatory state modulating neuronal gene expression
changes in response to Aβ/AD pathology.
Methods
Compounds. PLX3397 (pexidartinib) was synthesized following the published
procedure62. The synthesis of 2-fluoro-3-[(7-aza-5-methyl-3-indolyl)methyl]-6-
[(5-fluoro-2-methoxy-3 pyridyl)methyl]aminopyridine (PLX5622), followed the
procedure detailed in Supplementary Methods. For long term dosing, the com-
pounds were formulated in AIN-76A standard chow by Research Diets Inc. at
1200 ppm (PLX5622), 300 ppm (PLX5622), 600 ppm (PLX3397), and 75 ppm
(PLX3397). Instructions for the preparation of PLX5622 gavage dosing suspensions
and chow are found in Supplementary Methods.
Animal Treatments. All animal experiments were approved by the UC Irvine
Institutional Animal Care and Use Committee and were conducted in compliance
with all relevant ethical regulations for animal testing and research. The 3xTg-
AD63 and 5xFAD64 mouse models have been previously described in detail. For
3xTg-AD genotyping, the following primer sequences were used: APP Forward
5′ – GCT TGC ACC AGT TCT GGA TGG – 3′, APP Reverse 5′ – GAG GTA TTC
AGT CAT GTG CT– 3′, PS1 Forward 5′ CAC ACG CAA CTC TGA CAT GCA
CAG GC – 3′, and PS1 Reverse 5′ AGG CAG GAA GAT CAC GTG TTC AAG
TAC – 3′. For 5xFAD genotyping, the primer sequences used were PS1 Forward 5′ -
AAT AGA GAA CGG CAG GAG CA – 3′ and PS1 Reverse 5′ - GCC ATG AGG
GCA CTA ATC AT – 3′. At the end of treatments, mice were euthanized via CO2
inhalation and transcardially perfused with 1X phosphate buffered saline (PBS).
For all studies, brains were removed, and hemispheres separated along the midline.
Brain halves were either flash frozen for subsequent biochemical analysis or drop-
fixed in 4% paraformaldehyde (PFA (Thermo Fisher Scientific, Waltham, MA)) for
immunohistochemical analysis. Fixed half brains were sliced at 40 μm using a Leica
SM2000R freezing microtome. The flash-frozen hemispheres were microdissected
into cortical, hippocampal, and thalamic/striatal regions and then ground with a
mortar and pestle to yield a fine powder. One-half of the powder from cortical and
thalamic regions was homogenized in 500 or 250 μl Tissue Protein Extraction
Reagent (TPER (Life Technologies, Grand Island, NY)), respectively, with protease
(Roche, Indianapolis, IN) and phosphatase inhibitors (Sigma-Aldrich, St. Louis,
MO) and centrifuged at 100,000 g for 1 h at 4 °C to generate TPER-soluble frac-
tions. For formic acid-fractions, pellets from TPER-soluble fractions were homo-
genized in 500 or 250 μl 70% Formic Acid and centrifuged at 100,000 g for 1 h at
4 °C. Protein concentration in each fraction was determined via Bradford65 and
Lowry assays (Bio-Rad, per manufacturer’s instructions). For RNA analyses, the
second half of powder was processed with an RNA Plus Universal Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s instructions.
Human tissue. Human postmortem tissue from non-demented, non-demented
high pathology, and Alzheimer’s disease subjects was obtained from the Alzhei-
mer’s Disease Research Center, UC Irvine with consent from the UC Irvine Ethics
Committee. Neuropathological examination included Braak and Braak staging for
plaques and tangles and diagnosis of neuropathological AD using National Insti-
tute on Aging-Reagan criteria. Human sections were obtained from 4% PFA drop-
fixed regions of the middle frontal gyrus of the cortex and processed into 25 µm
thick floating sections.
Behavioral Testing. ANY-Maze software was employed to video-record and track
animal behavior. The following behavioral paradigms were carried out according to
established protocols10,17,64 and described briefly below:
Elevated plus maze (EPM): Mice were placed in the center of an elevated plus
maze (arms 6.2 × 66 cm, with side walls 15 cm high on two closed arms, elevated
46 cm above the ground) for 5 min to assess anxiety.
Open field (OF): In brief, mice were placed in a white box (33.7 cm L×27.3 cm
W×21.6 cmH) for 5 min to assess motor function and anxiety.
Spontaneous Alternation Y-Maze: Animals were placed in a Y-Maze (22 cm
long×11.5 cm wide, sloping to 2.5 cm wide at the bottom with sidewalls 12.7 cm
high) facing the back wall of the arm. Each mouse was allowed to explore the
arena for 8 min. Visual extra- and intra-maze cues were provided to allow mice
to create a spatial map of the maze. During the trial, the sequence of arm entries
was scored live, as well as video-recorded for later analysis if needed. The
number of triads was determined by counting the sequential entry into three
different arms of the maze.
Morris water maze (MWM): Mice were placed in a plastic circular pool filled
with opaque tap water (water mixed with water-soluble white paint). A white
plastic platform was submerged 0.5 cm below the surface of the water. Distinct two-
dimensional visual cues were positioned around the perimeter of the pool. The pool
was visually divided into four quadrants, and the hidden platform was placed in
one of these quadrants (#2), where it remained throughout the acquisition trials.
Visual cues were taped to the walls to allow mice to create a spatial map during
acquisition of the task. At the beginning of each acquisition trial, mice were placed
on the platform for 10 s and then subsequently placed in the pool (quadrants were
pseudorandomized) to swim freely for 60 s or until the platform was located. After
all mice completed four trials, they were returned to their home cages. Twenty-four
Fig. 7 Administration of an analogous CSF1R inhibitor, PLX3397 (75 ppm and 600 ppm), to 5xFAD mice. a Experimental design. b Terminal PK of wild-type
and 5xFAD groups treated with PLX3397. c, d Confocal images of tissue stained for dense-core plaques (Thio-S in green) and immunolabeled for microglia
(IBA1 in red) in 600 ppm PLX3397-treated and control mice. Scale bar= 75 μm. e–h Sections of the retrosplenial (RS) and somatosensory (SS) cortex,
respectively, stained for dense-core plaques (Thio-S in green) and immunolabeled for microglia (IBA1 in red) in mice treated with control or 75 ppm
PLX3397. Scale bar= 75 μm. i Quantification of IBA1+ cell number in the RS and SS cortex. (SS Cortex: PLX5622 v 5xFAD+ PLX5622, p= 0.045) Two-
way ANOVA with Tukey’s post hoc test; n= 4 for Wild-type, n= 6 for PLX3397, n= 6 for 5xFAD, n= 4 for 5xFAD+ PLX3397. j–k, Quantification of
cortical plaque number and volume, respectively, revealing no change in these measures with 75 ppm PLX3397 treatment in 5xFAD mice. Two-tailed
independent t-test; n= 4–5 for 5xFAD, n= 4–5 for 5xFAD+ PLX3397. Statistical significance is denoted by *p < 0.05. Statistical trends are denoted by #p
< 0.10. Error bars indicate SEM
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a Genes changes in all three brain regions
(wild-type vs. 5xFAD mice)
c Disease-associated microglial genes
b Microglial homeostatic genes
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Fig. 8 Remaining plaque-forming microglia in the microdissected hippocampus exhibit a DAM expression profile. a All gene expression changes where p <
0.05 for Wild-type (WT) vs. 5xFAD in all three brain regions shown as Log(2) fold change for each gene, for the 9 relevant comparisons (5xFAD vs. WT in
cortex, hippocampus, or thalamus, 5xFAD+ PLX5622 vs. 5xFAD in cortex, hippocampus, or thalamus, and WT+ PLX5622 vs. WT in cortex, hippocampus,
or thalamus). b RPKM values shown for a subset of the homeostatic microglial genes from (a), including Csf1r, Cx3cr1, C1qa, Hexb, Siglech, and Spi1. c RPKM
values shown for a subset of the disease-associated microglial genes from (a), including Ccl6, Clec7a, Cst7, Ctsd, Ctsz, and Itgax. RPKM values for all genes/
brain regions can be found at [https://rnaseq.mind.uci.edu/green/ad_plx/gene_search.php]. n= 4 per group for all analyses. Error bars indicate SEM
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hours after the last day of acquisition testing, the platform was removed and the
mice were subjected to a 60 s probe trial to assess spatial memory for the platform
location.
Contextual Fear conditioning (CFC): Behavior was scored live and video-
recorded using 1–0 sampling every 10 s, with a 1 denoting positive freezing
behavior (total lack of body movement except respiration) and 0 indicating the
absence of freezing behavior. In the training trial, mice were placed in a fear-
conditioning chamber (Gemini, San Diego Instruments; 24.1 cm L×20.3 cm
W×20.3 cmH) to explore for 2 min before receiving one foot shock (3 s, 0.2 mA).
Thirty seconds following the shock, animals returned to their home cage. Later
24 h, testing was conducted, whereby animals were placed in the chamber to
explore for 5 min.
Flow Cytometry. Blood was drawn via cardiac puncture and incubated with
ammonium-chloride-potassium lysing buffer for red blood cell lysis. Blood
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leukocytes were subsequently blocked with anti-mouse CD16/32 (14–0161–81;
eBioscience) and stained with fluorophore-conjugated antibodies A700 anti-mouse
CD45 (103127; BioLegend), PE anti-mouse CD11b (101208; BioLegend), APC-Cy7
anti-mouse CD11c (117323; BioLegend), PE-Cy7 anti-mouse CD4 (100421; Bio-
Legend), APC anti-mouse CD8 (100711; BioLegend) and FITC anti-mouse CD19
(115505; BioLegend) as well as propidium iodide (PI; Invitrogen) for live/dead
discrimination. Data were acquired on a BD FACSAria II and analyzed using the
FlowJo software to assess peripheral cell counts. Gating was performed following
routinely used protocols, using FSC/SSC to exclude dead cells, cell debris and
doublets and propidium iodide to identify dead cells. At least 250,000 events were
captured by the cytometer and 30,000 single cells analyzed per group. Cells were
gated on CD45+PI− live singlets. Dead cells were excluded as propidium iodide
(PI)-positive. Populations of live singlets were then gated was percentages of CD45
+ PI- cells.
Confocal Microscopy. For Thioflavin-S (Thio-S) staining, free-floating sections
were washed with 1X PBS (1 × 5 min), followed by dehydration in a graded series of
ethanol (100%, 95%, 70%, 50%; 1 × 3 min each). The sections were incubated in
0.5% Thio-S (in 50% ethanol, Sigma-Aldrich) for 10 min. This was followed by 3 ×
5min washes with 50% ethyl alcohol and a final wash in 1X PBS (1 × 10 min). For
6E10 and Aβ42 immunohistochemistry, sections were briefly rinsed in 1X PBS (1 ×
5 min) and underwent antigen-retrieval via incubation in 90% Formic Acid (1 ×
4 min), followed by 4 × 4min washes in 1X PBS. Following Thio-S staining or
formic acid pretreatment (if required), sections underwent a standard indirect
immunohistochemical protocol. To that end, free-floating sections were washed
with 1X PBS (1 × 5 min), and immersed in normal serum blocking solution (5%
normal serum with 0.2% Triton-X100 in 1X PBS) for 60 min. Primary antibodies
and dilutions used are as follows: anti-ionized calcium-binding adapter molecule 1
(IBA1; 1:1000; 019–19741; Wako, Osaka, Japan), anti-Aβ1–16 (6E10; 1:1000;
803001; BioLegend, San Diego, CA), anti-A11 oligomers (A11; 1:100; AHB0052;
Thermo-Fisher Scientific), anti-amyloid fibrils OC (OC; 1:100; AB2286; EMD
Millipore; Burlington, MA), anti-Aβ1–42 (1:200; ab10148; Abcam), anti-CD68
(1:500; MCA1957; Bio-Rad, Hercules, CA), anti-CD11b (1:50, MCA711; Bio-Rad),
anti-β−amyloid [pyroglutamate-3] (p3GluAβ; 1:500; NBP1–44048; Novus Biolo-
gicals, Littleton, CO), anti-lysosomal associated membrane protein 1 (LAMP1;
1:200; sc-20011; Santa Cruz Biotechnology; Dallas, TX), anti-amyloid precursor
protein, c-terminal (APP; 1:500; 171610; Calbiochem, San Diego, CA), anti-S100β
(1:200; ab52642; Abcam, Cambridge, MA), anti-apolipoprotein E (ApoE; 1:100;
ab1906; Abcam), anti-claudin-5 (1:500; 35–2500; Invitrogen) and anti-glial fibril-
lary protein (GFAP; 1:1000; ab4674; Abcam). Thioflavin-S (Thio-S; Sigma-Aldrich)
staining was carried out as described above. Amylo-Glo (TR-300-AG; Biosensis,
Thebarton, South Australia, AU) staining was performed according to the man-
ufacturer’s instructions. Prussian blue staining (ab150674; Abcam) was carried out
according to manufacturer’s instructions. Total microglia and plaque counts/
volumes were obtained by imaging comparable sections of tissue from each animal
at the ×10, ×20, or ×63 objective, at multiple z-planes, followed by automated
analyses using Bitplane Imaris 7.5 spots or surfaces modules, respectively. Plaque
circularity was evaluated using ImageJ software. ApoE intensity within plaque cores
was measured using Bitplane Imaris 7.5 surfaces module. Hemisphere stitches were
imaged using StereoInvestigator Software on a Zeiss Imager.M2 Stereology Scope.
Three-dimensional reconstruction of microglia and plaques was generated using
the surfaces module of Bitplane Imaris 7.5.
Immunoblotting. Equal amounts of TPER-soluble protein (20 μg) were separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS□PAGE) on a
4–12% Bis/Tris gel (Bio-Rad, Hercules, CA), transferred to 0.20 μm nitrocellulose
membranes, blocked for 1 h in 5% (vol/vol) nonfat milk or bovine serum albumin
(BSA) in Tris□buffered saline (pH 7.5) supplemented with 0.2% Tween20. Anti-
bodies and dilutions used include anti-6E10 (6E10; 1:1000; 803001; BioLegend),
anti-APP C-Terminal (APP; 1:1000; 171610; Calbiochem, San Diego, CA) for C99
and C83, anti-ADAM10 (1:1000; ab1997; Abcam), anti-β-secretase 1 (BACE1;
1:1000; ab2077; Abcam), anti-Presenilin-1 (PS1; 1:1000; ab76083; Abcam), anti-
Presenilin enhancer 2 (PEN2; 1:500; ab18189; Abcam), anti-A11 (A11; 1:1000;
AHB0052; Thermo-Fisher Scientific), and anti-β-actin (1:10,000; MA5–15739;
Sigma-Aldrich). Blots were developed using Pico/Dura Western Blotting Detection
System (Pierce) and exposed to film for images. Quantitative densitometric ana-
lyses were performed on digitized images of immunoblots using the NIH program
ImageJ and band densities were normalized to β-actin. Uncropped scans of the
blots are presented in Supplementary Figure 10A and 10B and provided in Source
Data file.
Aβ ELISA. Isolated protein samples were transferred to a blocked MSD Human
(6E10) Aβ triplex ELISA plate (Aβ1–38, Aβ1–40, Aβ1–42) and incubated for two hours
at room temperature with an orbital shaker. The plate was then washed and
measurements obtained using a SECTOR Imager 2400, per the manufacturer’s
instructions (Meso Scale Discovery, Gaithersburg, MD).
RNA Sequencing. Whole transcriptome RNA sequencing (RNA-Seq) libraries
were produced from Wild-type (WT), PLX5622, 5xFAD, and 5xFAD+ PLX5622
mice treated from 1.5 to 7 months of age, brains that were microdissected into
Cortex, Hippocampus, and Thalamus (n= 4/group for each of the 3 brain regions
= 48 total samples). Briefly, 100–600 ng of RNA were depleted of ribosomal RNA,
fragmented, reverse transcribed and ligated to indexed sequencing adapters using
the KAPA RNA HyperPrep Kit with RiboErase. Amplified libraries were combined
into 4 pools of 12 libraries and sequenced on 4 lanes of a HiSeq4000 producing 50
bp single-end reads. This work used the Vincent J. Coates Genomics Sequencing
Laboratory at UC Berkeley, supported by NIH S10 OD018174
Instrumentation Grant.
Reads were mapped to the reference mouse genome (mm10) using STAR66
aligner and quantified with the featureCounts function of the Rsubread67 package
in R68. After filtering out low-count genes, count distributions were scaled using
the calcNormFactors function of the edgeR69 package. Transgene/human
alignments were not filtered out from mouse reads. Principal component analysis
was performed using the plotMDS function of the limma70 package in R.
Normalized counts were prepared and fitted to linear models using the voom and
lmfit functions of limma respectively. Gene ontology gene sets for mouse were
downloaded from http://bioinf.wehi.edu.au/software/MSigDB/. Competitive gene
set testing was performed using the camera function (limma package), which
calculates two-tailed p-values and FDR adjusted p-values (p < 0.1) using the
Benjamini and Hochberg method.
Nanostring analysis. RNA was extracted and purified from frozen half brains
using an RNA Plus Universal Mini Kit (Cat. #73404, Qiagen). For nCounter©
analysis, total RNA was diluted to 20 ng/μl and probed using a mouse nCounter©
Neuropathology Panel (Nanostring Technologies, Seattle, WA, USA). Counts for
target genes were normalized to the best fitting house-keeping genes as determined
by nSolver software.
Statistics. Every reported n is the number of biologically independent replicates.
No statistical methods were used to predetermine sample sizes; however, our
sample sizes are similar to those reported in recently published similar studies10,28.
Behavioral, biochemical, and immunohistological data were analyzed using either
two-tailed independent-samples t-test (Control vs. Wild-type (WT) or 5xFAD vs.
5xFAD+ PLX3397/PLX5622) in Microsoft Excel or as a one- (Diet: Control vs.
PLX3397/PLX5622 vs. Repopulation) or two-way ANOVA (Diet: Control vs.
PLX3397/PLX5622 and Genotype: WT vs. 5xFAD) using GraphPad Prism Version
6 (La Jolla, CA). Tukey’s post hoc tests were employed to examine biologically
relevant interactions from the two-way ANOVA regardless of statistical sig-
nificance of the interaction. For RNA analyses, moderated t-statistics and
Fig. 9 Microglia mediate downregulation of neuronal/plasticity genes in the hippocampus in response to AD pathology. a Venn diagram showing the
number of differentially expressed genes (adjusted (adj.) p < 0.05) for cortex, hippocampus, and thalamus for wild-type (WT) vs. 5xFAD mice. b Heatmap
of the adj. p-value and log(2) fold change for all 9 comparison groups (5xFAD vs. WT in cortex, hippocampus, or thalamus, 5xFAD+ PLX5622 vs. 5xFAD
in cortex, hippocampus, or thalamus, and WT+ PLX5622 vs. WT in cortex, hippocampus, or thalamus), as well as 3 comparisons between brain regions for
both WT and 5xFAD mice, for the transgene components in 5xFAD mice (App, Psen1, Thy1). c Heatmap of all 413 gene expression differences identified in
the hippocampus for wild-type vs. 5xFAD, expressed as log (2) fold change, and all 9 comparison groups included. Hippocampus for 5xFAD vs. WT and
5xFAD+ PLX5622 vs. 5xFAD highlighted by red border, showing that most significant gene expression changes induced by pathology do not occur in the
absence of microglia. d Downregulated genes in the hippocampus from (a), displayed as a heatmap of log(2) fold change differences for all 9 comparisons,
showing that the same genes are not downregulated in the absence of microglia (5xFAD+ PLX5622 vs. 5xFAD Hip). e RPKM values plotted on a log(2)
scale for a subset of plasticity genes from (d). f Five significantly upregulated and downregulated pathways for 5xFAD vs. wild-type hippocampus (red),
along with respective -log(10) p-values plotted: most upregulated pathways are related to immune function, while downregulated pathways are mainly
associated with neuronal and synaptic activity. The same pathways are displayed for the comparison between 5xFAD+ PLX5622 vs. 5xFAD hippocampus
(yellow), showing that the absence of microglia prevents the upregulation of immune pathways and the downregulation of synaptic pathways. Expression
difference denoted by *. Log(2) fold change and p-values indicated by respective scale bar. n= 4 per group for all analyses. Error bars indicate SEM
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corresponding p-values (raw) were calculated for each of the relevant comparisons
for each gene (5xFAD vs. WT in cortex, hippocampus, or thalamus, 5xFAD+
PLX5622 vs. 5xFAD in cortex, hippocampus, or thalamus, and WT+ PLX5622 vs.
WT in cortex, hippocampus, or thalamus), as well as the comparisons between
brain regions (cortex vs. hippocampus, cortex vs. thalamus, and hippocampus vs.
thalamus for both WT and 5xFAD mice) using the eBayes function in limma. Raw
p-values were adjusted across all comparisons to account for multiple testing using
the decideTests function (Benjamini-Hochberg method). Genes with an adjusted
p-value below 0.05 were considered differentially expressed. Data distribution was
assumed to be normal, but this was not formally tested. Symbols denote significant
differences between groups: *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical trends
are accepted at p < 0.10 (#). Data are presented as raw means and standard error of
the mean (SEM).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
A searchable database with all RPKM values can be found at [http://rnaseq.mind.uci.edu/
green/ad_plx/gene_search.php]. The atomic coordinates and structure factors of CSF1R
in complex with PLX5622 (PDB accession code: 6N33) can be downloaded from the
website of Protein Data Bank, [www.rcsb.org]. The RNA-Seq data has been deposited in
GEO (accession number: GSE134151). Uncropped blots can be found in Supplementary
Figure 10 and the Source Data file. Additional data that support the findings of this study
are available from the corresponding author upon reasonable request.
Received: 14 January 2019 Accepted: 26 July 2019
References
1. Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer’s
disease: an updated hypothetical model of dynamic biomarkers. Lancet
Neurol. 12, 207–216 (2013).
2. Hardy, J. The amyloid hypothesis for Alzheimer’s disease: a critical
reappraisal. J. Neurochem. 110, 1129–1134 (2009).
3. Karch, C. M. & Goate, A. M. Alzheimer’s disease risk genes and mechanisms
of disease pathogenesis. Biol. Psychiatry 77, 43–51 (2015).
4. Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and
EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet. 43,
436–441 (2011).
5. Guerreiro, R. et al. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med.
368, 117–127 (2013).
6. Huang, K. L. et al. A common haplotype lowers PU.1 expression in myeloid cells
and delays onset of Alzheimer’s disease. Nat. Neurosci. 20, 1052–1061 (2017).
7. Hickman, S. E., Allison, E. K. & El Khoury, J. Microglial dysfunction and
defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice.
J. Neurosci. 28, 8354–8360 (2008).
8. Daria, A. et al. Young microglia restore amyloid plaque clearance of aged
microglia. EMBO J (2016).
9. Hellwig, S. et al. Forebrain microglia from wild-type but not adult 5xFAD
mice prevent amyloid-beta plaque formation in organotypic hippocampal slice
cultures. Sci. Rep. 5, 14624 (2015).
10. Spangenberg, E. E. et al. Eliminating microglia in Alzheimer’s mice prevents
neuronal loss without modulating amyloid-beta pathology. Brain 139,
1265–1281 (2016).
11. Grathwohl, S. A. et al. Formation and maintenance of Alzheimer’s disease
beta-amyloid plaques in the absence of microglia. Nat. Neurosci. 12,
1361–1363 (2009).
12. Jankowsky, J. L. et al. Persistent amyloidosis following suppression of Abeta
production in a transgenic model of Alzheimer disease. PLoS Med 2, e355
(2005).
13. Su, Y. & Chang, P. T. Acidic pH promotes the formation of toxic fibrils from
beta-amyloid peptide. Brain Res 893, 287–291 (2001).
14. Tseng, B. P. et al. Deposition of monomeric, not oligomeric, Abeta mediates
growth of Alzheimer’s disease amyloid plaques in human brain preparations.
Biochemistry 38, 10424–10431 (1999).
15. Hu, X. et al. Amyloid seeds formed by cellular uptake, concentration, and
aggregation of the amyloid-beta peptide. Proc. Natl. Acad. Sci. USA 106,
20324–20329 (2009).
16. Sole-Domenech, S., Cruz, D. L., Capetillo-Zarate, E. & Maxfield, F. R. The
endocytic pathway in microglia during health, aging and Alzheimer’s disease.
Ageing Res Rev (2016).
17. Elmore, M. R. et al. Colony-stimulating factor 1 receptor signaling is necessary
for microglia viability, unmasking a microglia progenitor cell in the adult
brain. Neuron 82, 380–397 (2014).
18. Rice, R. A. et al. Elimination of Microglia Improves Functional Outcomes
Following Extensive Neuronal Loss in the Hippocampus. J. Neurosci. 35,
9977–9989 (2015).
19. Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated
microglia. Nature 541, 481–487 (2017).
20. Pascual, O., Ben Achour, S., Rostaing, P., Triller, A. & Bessis, A. Microglia
activation triggers astrocyte-mediated modulation of excitatory
neurotransmission. Proc. Natl. Acad. Sci. USA 109, E197–E205 (2012).
21. Kayed, R. et al. Fibril specific, conformation dependent antibodies recognize
a generic epitope common to amyloid fibrils and fibrillar oligomers
that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 18
(2007).
22. Kayed, R. et al. Common structure of soluble amyloid oligomers implies
common mechanism of pathogenesis. Science 300, 486–489 (2003).
23. Harigaya, Y. et al. Amyloid beta protein starting pyroglutamate at position 3 is
a major component of the amyloid deposits in the Alzheimer’s disease brain.
Biochem Biophys. Res Commun. 276, 422–427 (2000).
24. Park, J. H. et al. Pathogenesis of cerebral microbleeds: In vivo imaging of
amyloid and subcortical ischemic small vessel disease in 226 individuals with
cognitive impairment. Ann. Neurol. 73, 584–593 (2013).
25. Davis, J. et al. Early-onset and robust cerebral microvascular accumulation of
amyloid beta-protein in transgenic mice expressing low levels of a
vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J.
Biol. Chem. 279, 20296–20306 (2004).
26. Tian, J., Shi, J., Smallman, R., Iwatsubo, T. & Mann, D. M. Relationships in
Alzheimer’s disease between the extent of Abeta deposition in cerebral blood
vessel walls, as cerebral amyloid angiopathy, and the amount of
cerebrovascular smooth muscle cells and collagen. Neuropathol. Appl
Neurobiol. 32, 332–340 (2006).
27. Dagher, N. N. et al. Colony-stimulating factor 1 receptor inhibition prevents
microglial plaque association and improves cognition in 3xTg-AD mice. J.
Neuroinflamm. 12, 139 (2015).
28. Olmos-Alonso, A. et al. Pharmacological targeting of CSF1R inhibits
microglial proliferation and prevents the progression of Alzheimer’s-like
pathology. Brain 139, 891–907 (2016).
29. Liao, F. et al. Murine versus human apolipoprotein E4: differential facilitation
of and co-localization in cerebral amyloid angiopathy and amyloid plaques in
APP transgenic mouse models. Acta Neuropathol. Commun. 3, 70
(2015).
30. Parhizkar, S. et al. Loss of TREM2 function increases amyloid seeding but
reduces plaque-associated ApoE. Nat Neurosci (2019).
31. Krasemann, S. et al. The TREM2-APOE Pathway Drives the Transcriptional
Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Immunity 47, 566–581 e9 (2017).
Fig. 10 Microglia seed plaques. All analyses listed in respective order for retrosplenial (RS) cortex, somatosensory (SS) cortex, and thalamus.
a Experimental design: 1.5-month-old wild-type (WT) and 5xFAD mice were administered PLX5622 (1200 ppm in chow) until 4 months of age. Diet was
withdrawn for 1 month to allow microglial repopulation. This figure was created with images adapted from Servier Medical Arts and is licensed under the
Creative Commons Attribution 3.0 Unported License [https://creativecommons.org/licenses/by/3.0/]. b Representative hemisphere stitches of sections
stained for dense core plaques (Thio-S in green) and immunolabeled for microglia (IBA1 in red). Scale bar= 1000 μm. c–e Images of dense-core plaque
staining (Thio-S in green) and microglia immunolabeling (IBA1 in red). Scale bar= 100 μm for C,D; 25 μm for E. f, IBA1+ cell number (WT v 5xFAD, p=
0.001, NS, p < 0.001; WT v PLX5622, p < 0.001, p < 0.001, p < 0.001; 5xFAD v 5xFAD+ PLX5622, p < 0.001, p < 0.001, p < 0.001; PLX5622 v Repopulation,
NS, p= 0.054, p= 0.008; 5xFAD+ PLX5622 v 5xFAD+ Repopulation, p= 0.006, p < 0.001, p < 0.001; WT v Repopulation, NS, p= 0.002, NS; 5xFAD v
5xFAD+ Repopulation, p < 0.001, p < 0.001, p= 0.027; Repopulation v. 5xFAD+ Repopulation, NS, NS, p < 0.001). Two-way ANOVA with Tukey’s post
hoc test; n= 5 for Wild-type, n= 4 for PLX5622, n= 4 for Wild-type+ Repopulation, n= 8 for 5xFAD, n= 9 for 5xFAD+ PLX5622, n= 6 for 5xFAD+
Repopulation. g Quantification of Thio-S+ plaque number (5xFAD v 5xFAD+ PLX5622, p < 0.001, p < 0.001, p= 0.007; 5xFAD+ PLX5622 v 5xFAD+
Repopulation, p < 0.001, p < 0.001, p= 0.001; 5xFAD v 5xFAD+ Repopulation, NS, NS, NS). One-way ANOVA with Tukey’s post hoc test; n= 7 for 5xFAD,
n= 9 for 5xFAD+ PLX5622, n= 6 for 5xFAD+ Repopulation. h Mean cortical plaque volumes (5xFAD v 5xFAD+ Repopulation, p= 0.048). Two-tailed
independent t-test; n= 7 for 5xFAD, n= 6 for 5xFAD+ Repopulation. I Images of dense-core plaques (Thio-S in blue) and astrocytes with GFAP (in green)
and S100β (in red). Scale bar= 100 μm. j GFAP+ astrocyte number in the SS cortex (WT v 5xFAD, p= 0.010; 5xFAD v 5xFAD+ PLX5622, p= 0.002;
5xFAD+ PLX5622 v 5xFAD+ Repopulation, p < 0.001; WT+ Repopulation v 5xFAD+ Repopulation, p < 0.009). Two-way ANOVA with Tukey’s post hoc
test; n= 4 for Wild-type, n= 4 for PLX5622, n= 4 for Wild-type+ Repopulation, n= 7 for 5xFAD, n= 10 for 5xFAD+ PLX5622, n= 6 for 5xFAD+
Repopulation. Statistical significance is denoted by *p < 0.05, **p < 0.01, and ***p < 0.001. NS, not significant (p > 0.10). Error bars indicate SEM
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11674-z
20 NATURE COMMUNICATIONS |         (2019) 10:3758 | https://doi.org/10.1038/s41467-019-11674-z | www.nature.com/naturecommunications
32. Andrew, R. J. et al. Lack of BACE1 S-palmitoylation reduces amyloid burden
and mitigates memory deficits in transgenic mouse models of Alzheimer’s
disease. Proc. Natl. Acad. Sci. USA 114, E9665–e9674 (2017).
33. Cummings, B. J. et al. Aggregation of the amyloid precursor protein within
degenerating neurons and dystrophic neurites in Alzheimer’s disease.
Neuroscience 48, 763–777 (1992).
34. Gowrishankar, S. et al. Massive accumulation of luminal protease-deficient
axonal lysosomes at Alzheimer’s disease amyloid plaques. Proc. Natl. Acad.
Sci. USA 112, E3699–E3708 (2015).
35. Condello, C., Yuan, P., Schain, A. & Grutzendler, J. Microglia constitute a
barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around
plaques. Nat. Commun. 6, 6176 (2015).
36. Wang, Y. et al. TREM2-mediated early microglial response limits diffusion
and toxicity of amyloid plaques. J. Exp. Med 213, 667–675 (2016).
37. Yuan, P. et al. TREM2 Haplodeficiency in Mice and Humans Impairs the
Microglia Barrier Function Leading to Decreased Amyloid Compaction and
Severe Axonal Dystrophy. Neuron 90, 724–739 (2016).
38. Najafi, A. R. et al. A limited capacity for microglial repopulation in the adult
brain. Glia (2018).
39. Keren-Shaul, H. et al. A unique microglia type associated with restricting
development of Alzheimer’s disease. Cell 169, 1276–1290 e17 (2017).
40. Elmore, M. R. P. et al. Replacement of microglia in the aged brain reverses
cognitive, synaptic, and neuronal deficits in mice. Aging Cell 17, e12832
(2018).
41. Rice, R. A. et al. Microglial repopulation resolves inflammation and promotes
brain recovery after injury. Glia 65, 931–944 (2017).
42. Bruttger, J. et al. Genetic cell ablation reveals clusters of local self-renewing
microglia in the mammalian central nervous system. Immunity 43, 92–106
(2015).
43. Faustino, J. V. et al. Microglial cells contribute to endogenous brain defenses
after acute neonatal focal stroke. J. Neurosci. 31, 12992–13001 (2011).
44. Rademakers, R. et al. Mutations in the colony stimulating factor 1 receptor
(CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids.
Nat. Genet. 44, 200–205 (2011).
45. Tada, M. et al. Characteristic microglial features in patients with hereditary
diffuse leukoencephalopathy with spheroids. Ann. Neurol. 80, 554–565 (2016).
46. Bateman, R. J. et al. Autosomal-dominant Alzheimer’s disease: a review and
proposal for the prevention of Alzheimer’s disease. Alzheimers Res. Ther. 3, 1
(2011).
47. Morris, J. C. et al. Pittsburgh compound B imaging and prediction of
progression from cognitive normality to symptomatic Alzheimer disease.
Arch. Neurol. 66, 1469–1475 (2009).
48. Vlassenko, A. G., Benzinger, T. L. & Morris, J. C. PET amyloid-beta imaging
in preclinical Alzheimer’s disease. Biochem. Biophys. Acta 1822, 370–379
(2012).
49. Vlassenko, A. G. et al. Imaging and cerebrospinal fluid biomarkers in early
preclinical alzheimer disease. Ann. Neurol. 80, 379–387 (2016).
50. Fuhrmann, M. et al. Microglial Cx3cr1 knockout prevents neuron loss in a
mouse model of Alzheimer’s disease. Nat. Neurosci. 13, 411–413 (2010).
51. Hong, S. et al. Complement and microglia mediate early synapse loss in
Alzheimer mouse models. Science 352, 712–716 (2016).
52. Park, J. et al. A 3D human triculture system modeling neurodegeneration and
neuroinflammation in Alzheimer’s disease. Nat. Neurosci. 21, 941–951 (2018).
53. Heckmann, B. L. et al. LC3-Associated Endocytosis Facilitates beta-Amyloid
Clearance and Mitigates Neurodegeneration in Murine Alzheimer’s Disease.
Cell (2019).
54. Giraldo, M. et al. Variants in triggering receptor expressed on myeloid cells 2
are associated with both behavioral variant frontotemporal lobar degeneration
and Alzheimer’s disease. Neurobiol. Aging 34, 2077.e11–8 (2013).
55. Gonzalez Murcia, J. D. et al. Assessment of TREM2 rs75932628 association
with Alzheimer’s disease in a population-based sample: the Cache County
Study. Neurobiol. Aging 34, 2889.e11–3 (2013).
56. Roussos, P. et al. The triggering receptor expressed on myeloid cells 2
(TREM2) is associated with enhanced inflammation, neuropathological
lesions and increased risk for Alzheimer’s dementia. Alzheimers Dement 11,
1163–1170 (2015).
57. Ulrich, J. D. et al. Altered microglial response to Abeta plaques in APPPS1-21
mice heterozygous for TREM2. Mol. Neurodegener. 9, 20 (2014).
58. Venegas, C. et al. Microglia-derived ASC specks cross-seed amyloid-β in
Alzheimer’s disease. Nature 552, 355–361 (2017).
59. Baik, S. H., Kang, S., Son, S. M. & Mook-Jung, I. Microglia contributes to
plaque growth by cell death due to uptake of amyloid beta in the brain of
Alzheimer’s disease mouse model. Glia 64, 2274–2290 (2016).
60. Chung, H., Brazil, M. I., Soe, T. T. & Maxfield, F. R. Uptake, degradation, and
release of fibrillar and soluble forms of Alzheimer’s amyloid beta-peptide by
microglial cells. J. Biol. Chem. 274, 32301–32308 (1999).
61. Moore, Z., Taylor, J. M. & Crack, P. J. The involvement of microglia in
Alzheimer’s disease: a new dog in the fight. Br. J. Pharmacol. (2018).
62. Tap, W. D. et al. Structure-guided blockade of CSF1R kinase in tenosynovial
giant-cell tumor. N. Engl. J. Med 373, 428–437 (2015).
63. Oddo, S. et al. Triple-transgenic model of alzheimer’s disease with plaques and
tangles. Neuron 39, 409–421 (2003).
64. Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration,
and neuron loss in transgenic mice with five familial Alzheimer’s disease
mutations: potential factors in amyloid plaque formation. J. Neurosci. 26,
10129–10140 (2006).
65. Green, K. N., Khashwji, H., Estrada, T. & Laferla, F. M. ST101 induces a novel
17 kDa APP cleavage that precludes Abeta generation in vivo. Ann. Neurol.
69, 831–844 (2011).
66. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29,
15–21 (2013).
67. Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and
scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
68. R Core Team. R: A Language and Environment for Statistical Computing. (The
R Foundation for Statistical Computing, Vienna, Austria, 2017).
69. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor
package for differential expression analysis of digital gene expression data.
Bioinformatics 26, 139–140 (2010).
70. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-
sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
Acknowledgements
This work was supported by the National Institutes of Health under awards
R01NS083801 (NINDS), R01AG056768 (NIA), and P50AG016573 (NIA) to K.N.G.,
AARF-16–442762 (Alzheimer’s Association) to L.A.H. and F31AG059367 (NIA) and
T32AG00096 (NIA) to E.S. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National Institutes of Health. X-ray
diffraction data were collected at the Advanced Light Source, which is a DOE Office of
Science User Facility under contract no. DE-AC02–05CH11231. We thank Dan Hoang,
Karla Abad-Torrez, Ken Nguyen, and Dr. Michael Phelan for the setting up of gene
expression data.
Author contributions
E.S. conceived and performed experiments, analyzed data, and wrote the manuscript. P.L.
Severson provided expertize and analyzed data. L.A.H. and J.C. performed experiments
and analyzed data. J.Z., E.A.B., Y.Z., W.S., and J.L. designed and performed experiments
and analyzed data. N.Y.P. performed analyzed data. G.H., A.R., G.T., J.W., M.N., P.I.,
C.Z., and G.B. designed and performed experiments and analyzed data. P.Singh, S.B. and
B.L.W. provided expertize and feedback. K.N.G. conceived experiments, wrote the
manuscript, provided supervision, and secured funding.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-11674-z.
Competing interests: P.L.Severson, J.Z., E.A.B., Y.Z., W.S., J.L., G.H., A.R., G.T., J.W.,
M.N., P.Singh, S.B., P.I., C.Z., G.B., and B.L.W. are employees of Plexxikon Inc.; the
remaining authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Peer review information: Nature Communications thanks Oleg Butovsky and other
anonymous reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11674-z ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3758 | https://doi.org/10.1038/s41467-019-11674-z | www.nature.com/naturecommunications 21
